Savant Capital LLC lessened its stake in AbbVie Inc (NYSE:ABBV) by 3.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 61,511 shares of the company’s stock after selling 1,936 shares during the quarter. Savant Capital LLC’s holdings in AbbVie were worth $4,473,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Van Leeuwen & Company LLC increased its stake in AbbVie by 4.1% in the fourth quarter. Van Leeuwen & Company LLC now owns 3,296 shares of the company’s stock valued at $304,000 after acquiring an additional 130 shares during the last quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO grew its stake in shares of AbbVie by 0.3% in the 2nd quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 44,147 shares of the company’s stock valued at $3,210,000 after purchasing an additional 147 shares during the period. Weatherly Asset Management L. P. grew its stake in shares of AbbVie by 1.8% in the 2nd quarter. Weatherly Asset Management L. P. now owns 8,317 shares of the company’s stock valued at $605,000 after purchasing an additional 151 shares during the period. BTIM Corp. grew its stake in shares of AbbVie by 0.6% in the 2nd quarter. BTIM Corp. now owns 27,263 shares of the company’s stock valued at $1,983,000 after purchasing an additional 154 shares during the period. Finally, Verus Financial Partners Inc. boosted its holdings in shares of AbbVie by 5.9% in the 2nd quarter. Verus Financial Partners Inc. now owns 2,786 shares of the company’s stock worth $203,000 after acquiring an additional 154 shares in the last quarter. Institutional investors and hedge funds own 70.03% of the company’s stock.

In related news, Director Roxanne S. Austin acquired 55,000 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was bought at an average price of $65.86 per share, for a total transaction of $3,622,300.00. Following the acquisition, the director now directly owns 92,114 shares of the company’s stock, valued at $6,066,628.04. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Roxanne S. Austin acquired 11,500 shares of the firm’s stock in a transaction dated Wednesday, June 26th. The stock was bought at an average price of $67.50 per share, with a total value of $776,250.00. Following the acquisition, the director now directly owns 52,114 shares in the company, valued at $3,517,695. The disclosure for this purchase can be found here. Insiders have acquired a total of 152,452 shares of company stock worth $10,128,541 in the last ninety days. 0.08% of the stock is owned by company insiders.

A number of research analysts have recently weighed in on ABBV shares. Credit Suisse Group set a $78.00 price target on AbbVie and gave the company a “sell” rating in a research note on Friday, April 26th. Citigroup reaffirmed a “hold” rating on shares of AbbVie in a research note on Wednesday, June 26th. Goldman Sachs Group assumed coverage on AbbVie in a research report on Tuesday, May 28th. They set a “neutral” rating and a $84.00 target price on the stock. ValuEngine lowered AbbVie from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 26th. Finally, Wolfe Research upgraded AbbVie from an “underperform” rating to a “peer perform” rating in a research report on Thursday, June 27th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $92.05.

Shares of AbbVie stock traded down $0.79 on Friday, reaching $66.73. 3,558,708 shares of the company were exchanged, compared to its average volume of 10,102,875. The stock’s 50 day moving average price is $67.68 and its 200-day moving average price is $76.15. The company has a market cap of $98.19 billion, a P/E ratio of 8.44, a price-to-earnings-growth ratio of 1.58 and a beta of 0.96. AbbVie Inc has a 1-year low of $62.66 and a 1-year high of $98.70.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 26th. The company reported $2.26 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.21 by $0.05. AbbVie had a negative return on equity of 182.70% and a net margin of 12.62%. The company had revenue of $8.26 billion during the quarter, compared to analysts’ expectations of $8.09 billion. During the same quarter in the previous year, the business earned $2.00 earnings per share. The firm’s revenue for the quarter was down .3% on a year-over-year basis. On average, equities research analysts expect that AbbVie Inc will post 8.88 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 15th. Shareholders of record on Monday, July 15th were paid a dividend of $1.07 per share. This represents a $4.28 annualized dividend and a yield of 6.41%. The ex-dividend date was Friday, July 12th. AbbVie’s payout ratio is currently 54.11%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Read More: What is a CD ladder?

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.